- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04770935
To Assess the Pharmacokinetics and Safety and Tolerability of Efanesoctocog Alfa (BIVV001)in Adults With Type 2N and 3 Von Willebrand Disease (VWD)
A Phase 1, Open-Label Study to Assess the Pharmacokinetics, and Safety and Tolerability of a Single Intravenous Injection of rFVIIIFc-VWF-XTEN (BIVV001) in Adults With Type 2N and 3 Von Willebrand Disease (VWD)
Primary Objective:
-To characterize the pharmacokinetics (PK) of BIVV001 after a single intravenous (IV) administration, as assessed by factor VIII (FVIII) activity determined by the one-stage activated partial thromboplastin time (aPPT) clotting assay, as well as, BIVV001 capture chromogenic Coatest FVIII activity assay
Secondary Objective:
-To assess the safety and tolerability of a single IV dose of BIVV001 in adult patients with type 2N and 3 VWD
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Duration of each part of the study for one participant:
Total study duration: Up to 57 days.
- Screening: up to 28 days.
- Up to 29 days of safety observation following the IV BIVV001 dose administration (this period includes PK sampling up to the first 10 days following administration).
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Lille, France, 59037
- Investigational Site Number :2500001
-
Nantes, France, 44093
- Investigational Site Number :2500002
-
-
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- University of Iowa_Investigational Site Number :8400002
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- Hemophilia Center of Western Pennsylvania_Investigational Site Number :8400001
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion criteria :
-- Male and/or female participant, between 18 and 65 years of age, inclusive at the time of informed consent.
- The participant has been diagnosed with hereditary type 3 VWD or type 2N VWD as documented in historical medical records OR a documented genotype known to produce VWD type 3 or 2N VWD.
- Type 3 VWD participants are included if they have a medical history of at least 25 exposure days to VWF and factor VIII-containing coagulation factor concentrates
- Type 2N VWD participants are included if the use of DDAVP is deemed insufficient or contraindicated, as assessed by the Investigator, or if they have required prior use of VWF- and FVIII- containing coagulation factor concentrates.
Exclusion criteria:
- Hereditary or acquired coagulation disorder other than VWD (including qualitative and quantitative platelet disorders, and thrombocytopenia < 100,000 cells/uL at Screening)
- The participant has a FVIII activity levels >20 IU/dL, at Screening
- History or presence of a VWF inhibitor or clinical suspicion of a VWF inhibitor
- History of a positive FVIII inhibitor test, defined as ≥0.6 BU/mL (by Nijmegen modified Bethesda assay) or a clinical suspicion of a FVIII inhibitor
- Positive FVIII inhibitor test, defined as ≥0.6 BU/mL, at Screening
- History of hypersensitivity or anaphylaxis associated with any FVIII- or VWF- containing product
- The participant has received or anticipates receiving systemic immunosuppressive or immunomodulatory treatment within 12 weeks prior to Baseline.
- The participant requires the use of acetylsalicylic acid, non-NSAID anti-platelets, and NSAIDs above the maximum dose product
- Patients currently on a prophylaxis regimen for the treatment of VWD that, in the Investigator's opinion, would preclude participation in the study due to the possible increased risk of bleeding associated with the requirement to withhold prophylaxis during the study.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: efanesoctocog alfa (BIVV001)
A single IV dose of BIVV001 will be administered to each patient
|
Pharmaceutical form:solution for injection Route of administration: intravenous injection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pharmacokinetic Parameter: Maximum plasma concentration observed (Cmax)
Time Frame: Day 1 to Day 10
|
Day 1 to Day 10
|
Pharmacokinetic Parameter: Terminal half-life (t½z)
Time Frame: Day 1 to Day 10
|
Day 1 to Day 10
|
Pharmacokinetic Parameter: Total Clearance (CL)
Time Frame: Day 1 to Day 10
|
Day 1 to Day 10
|
Pharmacokinetic Parameter: Volume of distribution at steady state (Vss)
Time Frame: Day 1 to Day 10
|
Day 1 to Day 10
|
Pharmacokinetic Parameter: Area under the activity time curve extrapolated to infinity (AUC∞)
Time Frame: Day 1 to Day 10
|
Day 1 to Day 10
|
Pharmacokinetic Parameter: Mean residence time (MRT)
Time Frame: Day 1 to Day 10
|
Day 1 to Day 10
|
Pharmacokinetic Parameter: Incremental recovery (IR)
Time Frame: Day 1 to Day 10
|
Day 1 to Day 10
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of participants with adverse events
Time Frame: Up to Day 29
|
Up to Day 29
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PKM16978
- 2020-004947-10 (EudraCT Number)
- U1111-1255-4463 (Other Identifier: UTN)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Von Willebrand's Disease (VWD)
-
OctapharmaRecruitingVWD - Von Willebrand's DiseaseFrance
-
VWD Connect FoundationRecruitingVWD - Von Willebrand's DiseaseUnited States
-
Assiut UniversityNot yet recruitingVWD - Von Willebrand's Disease
-
TakedaAvailableVon Willebrand Disease (VWD)
-
Fondazione Angelo Bianchi BonomiSintesi Research SrlActive, not recruitingType 3 Von Willebrand's DiseaseFinland, France, Germany, Hungary, Iran, Islamic Republic of, Italy, Netherlands, Spain, Sweden, United Kingdom
-
TakedaCompletedVon Willebrand Disease (VWD)Canada
-
TakedaCompletedVon Willebrand Disease (VWD)Germany
-
National Center for Research Resources (NCRR)University of North CarolinaCompletedVon Willebrand's Disease
-
TakedaNot yet recruitingVon Willebrand Disease (VWD)
-
Baxalta now part of ShireTakeda Development Center Americas, Inc.RecruitingVon Willebrand Disease (VWD)United States, Italy, Spain, Netherlands, Turkey, France, Austria, Germany, Russian Federation
Clinical Trials on efanesoctocog alfa (BIVV001)
-
Swedish Orphan BiovitrumSyneos HealthRecruitingHemophilia A, SevereItaly, Ireland, Belgium, Croatia, Greece, Spain, Sweden, Slovenia, United Kingdom, France, Germany, Norway, Austria, Czechia, Netherlands
-
Bioverativ, a Sanofi companyCompletedFactor VIII DeficiencyUnited States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, France, Germany, Greece, Hungary, Italy, Japan, Korea, Republic of, Mexico, Netherlands, Spain, Taiwan, United Kingdom
-
SanofiRecruitingHemophilia AUnited States
-
Bioverativ, a Sanofi companyActive, not recruitingHemophilia AUnited States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, China, France, Germany, Greece, Hungary, Ireland, Italy, Japan, Korea, Republic of, Netherlands, Spain, Sweden, Switzerland, Taiwan, Turkey, United Kingdom
-
Bioverativ, a Sanofi companyCompletedHemophilia ATurkey, Australia, Canada, France, Germany, Hungary, Ireland, Italy, Netherlands, Spain, Sweden, Switzerland, Taiwan, United Kingdom, United States
-
SanofiCompleted
-
Bioverativ, a Sanofi companyCompletedHemophilia AUnited States, Japan
-
ShireCompleted
-
Jonsson Comprehensive Cancer CenterAmgenCompletedLymphoma | Leukemia | Anemia | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Lymphoproliferative Disorder | Precancerous/Nonmalignant ConditionUnited States